Table 5.
Associations of exercise after diagnosis with MetS at 60-months post-diagnosis (NCEP-ATPIII criteria) among breast cancer survivors, stratified by waist circumference at baseline, BMI at baseline, menopausal status, Tamoxifen use, and radiotherapy, SBCSS, 2002–2006 (N=1614)a
| No exercise
|
Duration of exercise, per week, h<3.5
|
Duration of exercise, per week, h≥3.5
|
P for trend | P for interactionb | ||||
|---|---|---|---|---|---|---|---|---|
| N. MetS/non-MetS | OR | N. MetS/non-MetS | OR (95% CI)b | N. MetS/non-MetS | OR (95% CI)b | |||
| Stratified by waist circumference at baseline | ||||||||
| WC<88cm | 42/122 | 1.00 | 138/392 | 1.00(0.66–1.51) | 142/488 | 0.72(0.48–1.09) | 0.03 | |
| WC≥88cm | 30/15 | 1.00 | 83/43 | 0.96(0.45–2.08) | 75/46 | 0.75(0.35–1.62) | 0.37 | 0.83 |
| Stratified by BMI at baseline | ||||||||
| BMI<25 kg/m2 | 34/108 | 1.00 | 107/344 | 0.98(0.63–1.54) | 89/410 | 0.63(0.40–0.99) | 0.01 | |
| BMI≥25 kg/m2 | 38/29 | 1.00 | 114/91 | 1.02(0.57–1.84) | 128/124 | 0.77(0.44–1.36) | 0.18 | 0.60 |
| Stratified by menopausal status at baseline | ||||||||
| Premenopausal | 42/99 | 1.00 | 116/287 | 1.09(0.68–1.72) | 98/302 | 0.69(0.43–1.10) | 0.03 | |
| Postmenopausal | 30/38 | 1.00 | 105/148 | 0.84(0.47–1.50) | 119/232 | 0.62(0.35–1.09) | 0.04 | 0.85 |
| Stratified by Tamoxifen use | ||||||||
| Tamoxifen use | 47/71 | 1.00 | 108/242 | 0.75(0.47–1.20) | 119/299 | 0.57(0.36–0.91) | 0.01 | |
| No Tamoxifen use | 25/66 | 1.00 | 113/193 | 1.44(0.83–2.53) | 98/235 | 0.90(0.51–1.57) | 0.15 | 0.59 |
| Stratified by radiotherapy | ||||||||
| Radiotherapy | 26/42 | 1.00 | 64/132 | 0.84(0.44–1.59) | 68/163 | 0.60(0.32–1.13) | 0.07 | |
| No radiotherapy | 46/95 | 1.00 | 157/303 | 1.07(0.69–1.65) | 149/371 | 0.74(0.48–1.15) | 0.04 | 0.76 |
| Stratified by chemotherapy | ||||||||
| Chemotherapy | 68/130 | 1.00 | 203/407 | 0.95(0.66–1.38) | 206/504 | 0.67(0.47–0.97) | 0.01 | |
| No chmotherapy | 7/4 | 1.00 | 28/18 | 1.66(0.59–4.68) | 30/11 | 0.91(0.43–1.93) | 0.52 | -c |
a
Those cases with diabetes before diagnosis at baseline survey were excluded.
b
ORs from logistic regression models and adjusted for age at diagnosis, education, BMI at baseline, menopausal status at baseline, history of chronic disease (Charlson comorbidity score 0/≥1), TNM stage, and P-interaction across subgroups by the stratified factors.
c
Number of breast cancer patients without chemotherapy was very small (n=98).